{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:59:34Z","timestamp":1777438774164,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Myeloproliferative neoplasms (MPNs) are chronic hematologic disorders characterized by clonal proliferation of myeloid lineage cells, commonly driven by JAK2 mutations, and associated with significant thrombotic and hemorrhagic complications. Women of reproductive age with MPNs face unique challenges in selecting safe and effective contraception, as these disorders inherently increase thrombotic risk and may interact with hormonal contraceptive therapies. Estrogen\u2010containing contraceptives are contraindicated due to their association with venous and arterial thrombosis, while progestin\u2010only and non\u2010hormonal methods are generally safer but must be tailored to individual risks such as thrombocytopenia, prior thrombotic events, and disease\u2010modifying therapies. This review provides a comprehensive analysis of contraceptive options for women with MPNs, exploring the thrombotic and bleeding risks associated with different methods and the potential impact of MPN treatments, including JAK2 inhibitors, on contraceptive efficacy. By synthesizing current evidence, the review aims to guide clinicians in optimizing reproductive health for women with MPNs while minimizing the risks of their underlying hematologic condition.<\/jats:p>","DOI":"10.1111\/ejh.70014","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:50:18Z","timestamp":1753692618000},"page":"344-348","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Contraception in Myeloproliferative Neoplasms: A Pharmacological Review"],"prefix":"10.1111","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-5307","authenticated-orcid":false,"given":"Awni","family":"Alshurafa","sequence":"first","affiliation":[{"name":"Hematology Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Benkhadra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-3452","authenticated-orcid":false,"given":"Anas M.","family":"Babiker","sequence":"additional","affiliation":[{"name":"Hematology Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa M.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Hematology Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hematology Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3004"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.12.001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010019\u20105387\u20109"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27216"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0024363918816683"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769187"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506447"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010\u20102221"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102012.1.571"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144791"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2023.2247093"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21891"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21392"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP\u201004\u201023\u20106803"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000654304.29632.a7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2024.02.008"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2025.102824"},{"issue":"4","key":"e_1_2_9_19_1","first-page":"603","article-title":"Male Contraception","volume":"93","author":"Abbe C. R.","year":"2020","journal-title":"Yale Journal of Biology and Medicine"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.2019210"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010017\u20100400\u20103"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0046"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100040\u20101701474"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100032\u20101331153"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111181"},{"key":"e_1_2_9_26_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Estradiol\/Norethindrone Acetate Tablets \u201d2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020907s020s022lbl.pdf."},{"key":"e_1_2_9_27_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Ruxolitinib Tablets \u201d2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202192s023lbl.pdf."},{"key":"e_1_2_9_28_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Momelotinib Tablets \u201d2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216873s000lbl.pdf."},{"key":"e_1_2_9_29_1","unstructured":"\u201cHighlights of FDA Prescribing Information: Fedratinib Capsules \u201d2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212327s004lbl.pdf."},{"key":"e_1_2_9_30_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Pacritinib Capsules \u201d2022 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208712s000lbl.pdf."},{"key":"e_1_2_9_31_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Rivaroxaban Tablets \u201d2021 http:\/\/accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf."},{"key":"e_1_2_9_32_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Apixaban Tablets \u201d2016 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202155s012lbl.pdf."},{"key":"e_1_2_9_33_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Anagrelide Capsules \u201d2018 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020333s024lbl.pdf."},{"key":"e_1_2_9_34_1","unstructured":"FDA \u201cHighlights of FDA Prescribing Information: Warfarin Tablets \u201d2011 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7000.292a"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096\u20108652(199801)57:1<89::aid\u2010ajh18>3.0.co;2\u20104"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616683802"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27665"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:52:06Z","timestamp":1756799526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/ejh.70014"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70014","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2025-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}